Charles River (NYSE: CRL) EVP adds 25 shares in open-market buy

Rhea-AI Filing Summary

Charles River Laboratories International executive Joseph W. LaPlume bought 25 shares of common stock in an open-market purchase at $174.54 per share on March 3, 2026. Following this transaction, his directly held stake increased to 27,448 shares.

Insider Trade Summary

Net Buyer: 25 shares ($4,364)

Net Buy 1 txn

Insider LaPlume Joseph W

Role EVP, Corp Strategy & Develop

Bought 25 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	25	$174.54	$4K

Holdings After Transaction: Common Stock — 27,448 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaPlume Joseph W

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MA 01887

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Corp Strategy & Develop

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		P		25	A	$174.54	27,448	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Joseph W. LaPlume	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Charles River Laboratories (CRL) report?

Charles River Laboratories reported an insider stock purchase by executive Joseph W. LaPlume. He bought 25 shares of common stock in an open-market transaction at $174.54 per share, modestly increasing his direct ownership stake in the company.

Who is the insider involved in the latest CRL Form 4 filing?

The insider is Joseph W. LaPlume, Executive Vice President of Corporate Strategy & Development at Charles River Laboratories. He reported a direct open-market purchase of 25 shares of common stock, reflecting ongoing personal ownership in CRL shares.

How many Charles River (CRL) shares did the executive buy and at what price?

Executive Joseph W. LaPlume bought 25 shares of Charles River common stock. The reported purchase price was $174.54 per share in an open-market transaction, as disclosed in the Form 4 insider trading report.

What is Joseph W. LaPlume’s total CRL share ownership after this trade?

After the reported purchase, Joseph W. LaPlume directly owns 27,448 shares of Charles River common stock. The Form 4 filing states this total reflects his holdings immediately following the 25-share open-market acquisition.

Was the recent CRL insider transaction a purchase or a sale?

The recent insider transaction at Charles River Laboratories was a purchase. Executive Joseph W. LaPlume executed an open-market buy of 25 common shares, classified under transaction code “P” for a purchase in the Form 4 filing.